Company intelligence / Profile preview

Alimentary Health Ltd.

Ownership: Private
Employees: ~15
Development stage: Commercial

Overview

Alimentary Health's probiotic strain Bifidobacterium infantis 35624 (marketed as Bifantis) has been clinically proven to manage digestive issues including constipation, diarrhea, abdominal discomfort, urgency, gas and bloating. Studies published in The American Journal of Gastroenterology showed it was the only probiotic to demonstrate significant improvement in IBS symptoms.

Therapeutic areas: GastroenterologyImmunology
Modalities: ProbioticsPharmabiotics
Industry: Non-Drug Biotech

Drug pipeline

1 asset

B. infantis 35624

Commercial

Indications: Irritable Bowel Syndrome

Partnerships

Procter & GambleNorgineunnamed "major consumer healthcare company" for sports nutrition products

Beyond the preview

Go deeper on Alimentary Health Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alimentary Health Ltd..

Explore the full profile